Identification

Name
Carbetocin
Accession Number
DB01282
Type
Small Molecule
Groups
Approved
Description

Carbetocin is a drug used to control postpartum hemorrhage, bleeding after giving birth. It is an analogue of oxytocin, and its action is similar to that of oxytocin -- it causes contraction of the uterus.

Structure
Thumb
Synonyms
  • 1-Butanoic acid-2-(O-methyl-L-tyrosine)-1-carbaoxytocin
  • 1-Butyric acid-2-(3-(P-methoxyphenyl)-L-alanine)oxytocin
  • Carbetocino
  • Carbetocinum
  • Deamino-2-O-methyltyrosine-1-carbaoxytocin
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Duratocin InjectionLiquid100 mcgIntravenousFerring Pharmaceuticals1999-08-01Not applicableCanada
Categories
UNII
88TWF8015Y
CAS number
37025-55-1
Weight
Average: 988.161
Monoisotopic: 987.484787417
Chemical Formula
C45H69N11O12S
InChI Key
NSTRIRCPWQHTIA-DTRKZRJBSA-N
InChI
InChI=1S/C45H69N11O12S/c1-6-25(4)38-44(66)51-28(15-16-34(46)57)40(62)52-31(21-35(47)58)41(63)54-32(23-69-18-8-10-37(60)50-30(42(64)55-38)20-26-11-13-27(68-5)14-12-26)45(67)56-17-7-9-33(56)43(65)53-29(19-24(2)3)39(61)49-22-36(48)59/h11-14,24-25,28-33,38H,6-10,15-23H2,1-5H3,(H2,46,57)(H2,47,58)(H2,48,59)(H,49,61)(H,50,60)(H,51,66)(H,52,62)(H,53,65)(H,54,63)(H,55,64)/t25-,28-,29-,30-,31-,32-,33-,38-/m0/s1
IUPAC Name
(2S)-2-{[(2S)-1-[(3R,6S,9S,12S,15S)-12-[(2S)-butan-2-yl]-9-(2-carbamoylethyl)-6-(carbamoylmethyl)-15-[(4-methoxyphenyl)methyl]-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentaazacycloicosane-3-carbonyl]pyrrolidin-2-yl]formamido}-N-(carbamoylmethyl)-4-methylpentanamide
SMILES
[H][[email protected]]1(NC(=O)[[email protected]](CC2=CC=C(OC)C=C2)NC(=O)CCCSC[[email protected]](NC(=O)[[email protected]](CC(N)=O)NC(=O)[[email protected]](CCC(N)=O)NC1=O)C(=O)N1CCC[[email protected]]1C(=O)N[[email protected]@H](CC(C)C)C(=O)NCC(N)=O)[[email protected]@H](C)CC

Pharmacology

Indication

Used to control postpartum hemorrhage and bleeding after giving birth.

Structured Indications
Pharmacodynamics

Carbetocin is a drug used to control postpartum hemorrhage, bleeding after giving birth. It is sold under the trade name Duratocin. It is an analogue of oxytocin, and its action is similar to that of oxytocin; it causes contraction of the uterus.

Mechanism of action

Carbetocin binds to oxytocin receptors present on the smooth musculature of the uterus, resulting in rhythmic contractions of the uterus, increased frequency of existing contractions, and increased uterine tone. The oxytocin receptor content of the uterus is very low in the non-pregnant state, and increases during pregnancy, reaching a peak at the time of delivery.

TargetActionsOrganism
AOxytocin receptor
agonist
Human
Absorption

Bioavailability is 80% following intramuscular injection.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

40 minutes

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcebutololThe risk or severity of adverse effects can be increased when Carbetocin is combined with Acebutolol.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Aldesleukin.Approved
AliskirenThe risk or severity of adverse effects can be increased when Carbetocin is combined with Aliskiren.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Carbetocin.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Carbetocin is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Carbetocin.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Carbetocin.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Carbetocin.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Carbetocin is combined with Amyl Nitrite.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Carbetocin.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Apraclonidine.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Carbetocin.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Carbetocin.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Carbetocin.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Carbetocin is combined with Atenolol.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Carbetocin is combined with Azilsartan medoxomil.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Carbetocin.Experimental
BarbitalBarbital may increase the hypotensive activities of Carbetocin.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Carbetocin.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Carbetocin is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Carbetocin is combined with Bendroflumethiazide.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Carbetocin.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Carbetocin is combined with Betaxolol.Approved
BisoprololThe risk or severity of adverse effects can be increased when Carbetocin is combined with Bisoprolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Carbetocin.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Carbetocin is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Brimonidine.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Carbetocin.Approved, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Carbetocin is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Carbetocin.Approved, Investigational
CanagliflozinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Carbetocin is combined with Candesartan.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Carbetocin is combined with Captopril.Approved
Carboprost TromethamineThe risk or severity of adverse effects can be increased when Carboprost Tromethamine is combined with Carbetocin.Approved
CarteololThe risk or severity of adverse effects can be increased when Carbetocin is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carbetocin is combined with Carvedilol.Approved, Investigational
ChlorothiazideThe risk or severity of adverse effects can be increased when Carbetocin is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Carbetocin is combined with Chlorthalidone.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Carbetocin is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Cilnidipine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Clonidine.Approved
ClozapineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Carbetocin is combined with Conivaptan.Approved, Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Dapagliflozin.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Carbetocin is combined with Desflurane.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Dexmedetomidine.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Carbetocin is combined with Diclofenamide.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Carbetocin is combined with Diltiazem.Approved
DinoprostoneThe risk or severity of adverse effects can be increased when Dinoprostone is combined with Carbetocin.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Carbetocin is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Carbetocin is combined with Dipyridamole.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Doxazosin.Approved
DuloxetineCarbetocin may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Carbetocin is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Carbetocin is combined with Enalaprilat.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Carbetocin is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Carbetocin is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Carbetocin is combined with Eprosartan.Approved
EsmololThe risk or severity of adverse effects can be increased when Carbetocin is combined with Esmolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Carbetocin is combined with Etacrynic acid.Approved
FelodipineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Felodipine.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Carbetocin is combined with Fenoldopam.Approved
FimasartanThe risk or severity of adverse effects can be increased when Carbetocin is combined with Fimasartan.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Carbetocin is combined with Fosinopril.Approved
FurosemideThe risk or severity of adverse effects can be increased when Carbetocin is combined with Furosemide.Approved, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Guanfacine.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Carbetocin is combined with Halothane.Approved, Vet Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Carbetocin.Approved
HydralazineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Carbetocin is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Carbetocin is combined with Hydroflumethiazide.Approved
IloprostThe risk or severity of adverse effects can be increased when Carbetocin is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Carbetocin is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Carbetocin is combined with Indapamide.Approved
IndoraminThe risk or severity of adverse effects can be increased when Carbetocin is combined with Indoramin.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Carbetocin is combined with Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Carbetocin is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Carbetocin is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Carbetocin is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Carbetocin is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Isradipine.Approved
LabetalolThe risk or severity of adverse effects can be increased when Carbetocin is combined with Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Lacidipine.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Carbetocin is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Levobupivacaine.Approved
LevodopaCarbetocin may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Carbetocin is combined with Levosimendan.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Carbetocin is combined with Lisinopril.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Lofexidine.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Carbetocin is combined with Losartan.Approved
MannitolThe risk or severity of adverse effects can be increased when Carbetocin is combined with Mannitol.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Mecamylamine.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Carbetocin is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Carbetocin.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Carbetocin is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Carbetocin is combined with Methyldopa.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Carbetocin.Approved
MetipranololThe risk or severity of adverse effects can be increased when Carbetocin is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Carbetocin is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Carbetocin is combined with Metoprolol.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Carbetocin is combined with Minoxidil.Approved
MisoprostolThe risk or severity of adverse effects can be increased when Misoprostol is combined with Carbetocin.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Carbetocin is combined with Moexipril.Approved
MorphineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Morphine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Moxonidine.Approved
NabiloneThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nadolol.Approved
NebivololThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nebivolol.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nesiritide.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Carbetocin.Approved
NifedipineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nifedipine.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nitroprusside.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Carbetocin is combined with Obinutuzumab.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Carbetocin is combined with Olmesartan.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Carbetocin is combined with Oxprenolol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Carbetocin is combined with Paclitaxel.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Papaverine.Approved
PenbutololThe risk or severity of adverse effects can be increased when Carbetocin is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Carbetocin.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Carbetocin is combined with Perindopril.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Phenelzine.Approved
PhenobarbitalPhenobarbital may increase the hypotensive activities of Carbetocin.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Phentolamine.Approved
PindololThe risk or severity of adverse effects can be increased when Carbetocin is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Carbetocin is combined with Pipamperone.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Carbetocin is combined with Pramipexole.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Prazosin.Approved
PrimidonePrimidone may increase the hypotensive activities of Carbetocin.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Carbetocin is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Carbetocin is combined with Propranolol.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Carbetocin is combined with Quinapril.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Carbetocin is combined with Ramipril.Approved
RasagilineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Carbetocin is combined with Remifentanil.Approved
ReserpineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Reserpine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Carbetocin is combined with Riociguat.Approved
RisperidoneCarbetocin may increase the hypotensive activities of Risperidone.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Carbetocin is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Carbetocin is combined with Sacubitril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Carbetocin.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Selegiline.Approved, Investigational, Vet Approved
SevofluraneThe risk or severity of adverse effects can be increased when Carbetocin is combined with Sevoflurane.Approved, Vet Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Carbetocin is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Carbetocin is combined with Sotalol.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Carbetocin is combined with Spironolactone.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Carbetocin is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Carbetocin is combined with Sufentanil.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Tamsulosin.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Carbetocin is combined with Telmisartan.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Terazosin.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Carbetocin is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Carbetocin.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Carbetocin.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Thioridazine.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Carbetocin is combined with Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Tizanidine.Approved
TolazolineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Carbetocin is combined with Tolcapone.Approved, Withdrawn
TorasemideThe risk or severity of adverse effects can be increased when Carbetocin is combined with Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Carbetocin is combined with Trandolapril.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Carbetocin is combined with Tranylcypromine.Approved
TretinoinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Carbetocin is combined with Triamterene.Approved
ValsartanThe risk or severity of adverse effects can be increased when Carbetocin is combined with Valsartan.Approved, Investigational
VerapamilThe risk or severity of adverse effects can be increased when Carbetocin is combined with Verapamil.Approved
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
Not Available
External Links
Human Metabolome Database
HMDB15402
KEGG Drug
D07229
PubChem Compound
16681432
PubChem Substance
46509009
ChemSpider
16736854
BindingDB
50044677
ChEBI
59204
ChEMBL
CHEMBL3301668
Therapeutic Targets Database
DAP000269
PharmGKB
PA164743086
Wikipedia
Carbetocin
ATC Codes
H01BB03 — Carbetocin
AHFS Codes
  • 76:00.00
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingNot AvailablePostpartum Hemorrhage1
2CompletedScreeningPostpartum Hemorrhage1
2, 3CompletedPreventionCesarean Section1
3CompletedPreventionDelivery1
3CompletedPreventionPostpartum Hemorrhage1
3CompletedPreventionSevere Pre-eclampsia, Postpartum Condition or Complication1
3CompletedTreatmentObstetrics1
3RecruitingPreventionPost Partum Haemorrhage2
3RecruitingTreatmentPost Partum Hemorrhage1
3Unknown StatusPreventionPostpartum Hemorrhage / Severe Preeclampsia1
4CompletedNot AvailablePostpartum Hemorrhage1
4CompletedPreventionBlood Loss / Postpartum Hemorrhage1
4CompletedPreventionPostpartum Hemorrhage1
4CompletedSupportive CareEffect of Carbetocin on Cardiovascular System / Pregnancy1
4CompletedTreatmentAnemias / Haemorrhage1
4CompletedTreatmentEffects of; Anesthesia, in Pregnancy1
4CompletedTreatmentPost-Partum Hemorrhage / Uterine Atony1
4Not Yet RecruitingTreatmentCesarean Delivery1
4RecruitingPreventionPostpartum Hemorrhage2
4RecruitingTreatmentPregnancy1
4Unknown StatusPreventionCARBETOCIN FOR PREVENTION OF PLACENTAL RETAINED1
4Unknown StatusTreatmentPostpartum Hemorrhage / Uterine Atony1
Not AvailableCompletedBasic ScienceHyperalgesia / Pain / Sensitization, Central1
Not AvailableCompletedTreatmentAnaesthesia / Pregnancy Related1
Not AvailableCompletedTreatmentPostpartum Hemorrhage6
Not AvailableUnknown StatusTreatmentPostpartum Hemorrhage1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
LiquidIntravenous100 mcg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP-2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0265 mg/mLALOGPS
logP0.14ALOGPS
logP-3.6ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)11.42ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count10ChemAxon
Polar Surface Area362.51 Å2ChemAxon
Rotatable Bond Count18ChemAxon
Refractivity250.18 m3·mol-1ChemAxon
Polarizability101 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9806
Blood Brain Barrier-0.9678
Caco-2 permeable-0.774
P-glycoprotein substrateSubstrate0.8748
P-glycoprotein inhibitor IInhibitor0.5541
P-glycoprotein inhibitor IINon-inhibitor0.8748
Renal organic cation transporterNon-inhibitor0.8938
CYP450 2C9 substrateNon-substrate0.8785
CYP450 2D6 substrateNon-substrate0.7363
CYP450 3A4 substrateSubstrate0.6535
CYP450 1A2 substrateNon-inhibitor0.8997
CYP450 2C9 inhibitorNon-inhibitor0.7966
CYP450 2D6 inhibitorNon-inhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.7442
CYP450 3A4 inhibitorNon-inhibitor0.8166
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9196
Ames testNon AMES toxic0.8318
CarcinogenicityNon-carcinogens0.8517
BiodegradationNot ready biodegradable0.9703
Rat acute toxicity3.2094 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9403
hERG inhibition (predictor II)Inhibitor0.6577
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Oligopeptides
Alternative Parents
Cyclic peptides / Leucine and derivatives / Proline and derivatives / Macrolactams / N-acyl-alpha amino acids and derivatives / Alpha amino acid amides / Pyrrolidinecarboxamides / Anisoles / Phenoxy compounds / N-acylpyrrolidines
show 14 more
Substituents
Alpha-oligopeptide / Cyclic alpha peptide / Leucine or derivatives / Macrolactam / Proline or derivatives / N-acyl-alpha amino acid or derivatives / Alpha-amino acid amide / N-substituted-alpha-amino acid / Alpha-amino acid or derivatives / Phenoxy compound
show 32 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
heterodetic cyclic peptide (CHEBI:59204)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Vasopressin receptor activity
Specific Function
Receptor for oxytocin. The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system.
Gene Name
OXTR
Uniprot ID
P30559
Uniprot Name
Oxytocin receptor
Molecular Weight
42770.99 Da
References
  1. Engstrom T, Barth T, Melin P, Vilhardt H: Oxytocin receptor binding and uterotonic activity of carbetocin and its metabolites following enzymatic degradation. Eur J Pharmacol. 1998 Aug 21;355(2-3):203-10. [PubMed:9760035]
  2. Gimpl G, Postina R, Fahrenholz F, Reinheimer T: Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin. Eur J Pharmacol. 2005 Mar 7;510(1-2):9-16. [PubMed:15740719]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on May 17, 2007 10:46 / Updated on October 02, 2017 04:56